Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.

@article{Green2006ClinicalUA,
  title={Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.},
  author={Myke R. Green and Sajeel A. Chowdhary and Kristina M Lombardi and Lisa M Chalmers and Marc Chamberlain},
  journal={Expert review of neurotherapeutics},
  year={2006},
  volume={6 5},
  pages={635-52}
}
Primary CNS non-Hodgkin lymphoma (PCNSL) has been shown to be increasing in incidence. This appears to be a consequence of the increasing population of those older than 65 years of age in whom PCNSL occurs most often. PCNSL often has a favorable response to treatment and aggressive management may result in extended survival and, in a proportion of patients less than 65 years of age, cure. The majority of neuro-oncologist's advocate utilizing high-dose methotrexate (HD-MTX) as a platform for the… CONTINUE READING

From This Paper

Topics from this paper.
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…